Motif Bio PLC Update on timing of proposed US Public Offering (6040G)

TIDMMTFB

RNS Number : 6040G

Motif Bio PLC

09 August 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

This announcement contains inside information.

Motif Bio plc

("Motif Bio" or the "Company")

9 August 2016

UPDATE ON TIMING OF MOTIF BIO PROPOSED U.S. PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND APPLICATION FOR NASDAQ LISTING

Further to its announcement of 28 July 2016, Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that, as a result of market conditions, it has deferred pricing of its proposed public offering of American Depositary Shares ("ADSs") and listing of ADSs on the NASDAQ Global Market; however, the Company intends to continue to engage with investors. The Company will provide an update to the market in due course.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information please contact:

 
 Motif Bio plc                                                   info@motifbio.com 
  Richard Morgan (Chairman) 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                               +44 (0)20 3829 5000 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees (Broking)                               +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL        +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  PR & IR)                                                Mob: +44 (0)7980 541 893 
  Paul McManus                                            Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                                +49 (0)89 210 2280

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to complete in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEPPMJTMBTMTJF

(END) Dow Jones Newswires

August 09, 2016 02:01 ET (06:01 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024